MedTrace Logo

Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions

NCT01235156 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2010-11-05

No results posted yet for this study

Summary

Arrhythmia is a common disease that may be caused by various cardiovascular diseases. According to statistics, 500,000 people die of severe arrhythmia every year in China, In the United States, approximately 540,000 patients die each year.This study will evaluate the effectiveness safety of sulcardine sulfate tablets in the patients with premature ventricular contractions (and non-sustained VT).

Conditions

  • Premature Ventricular Contraction

Sponsors & Collaborators

  • Jiangsu Furui Pharmaceuticals Co., Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01235156 on ClinicalTrials.gov